Multiple myeloma is a hematologic cancer that is diagnosed in over 3,300 Canadians every year. The disease is incurable and is associated with damage to the bone, kidney and bone marrow, with a significant reduction in quality of life. The median life expectancy is about 5 years.
Since 2008, the Multiple Myeloma Research Unit team has participated in over 30 international and national clinical trials on various multiple myeloma therapies. Many of these studies have led to the approval of new drugs that are now available as standard treatment to improve care for multiple myeloma patients. The research unit is working to develop new therapeutic modalities that hold great promise for improving the survival rates and quality of life for patients with this disease.
In collaboration with the Hematopoietic Stem Cell Transplantation research team, the Multiple Myeloma research team has developed original studies on allogeneic transplantation and the treatment of multiple myeloma associated with a potential cure.